{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:39:39Z","timestamp":1773023979789,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10157-022-02288-9","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T19:07:51Z","timestamp":1666897671000},"page":"179-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Target phosphate and calcium levels in patients undergoing hemodialysis: a post-hoc analysis of the LANDMARK study"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-0132","authenticated-orcid":false,"given":"Kiryu","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hokuto","family":"Morohoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Sambe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The LANDMARK Investigators, Committees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2288_CR1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","volume":"42","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension. 2003;42:1050\u201365. https:\/\/doi.org\/10.1161\/01.HYP.0000102971.85504.7c.","journal-title":"Hypertension"},{"key":"2288_CR2","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New Engl J Med. 2000;342:1478\u201383. https:\/\/doi.org\/10.1056\/NEJM200005183422003.","journal-title":"New Engl J Med"},{"key":"2288_CR3","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1046\/j.1523-1755.62.s82.15.x","volume":"82","author":"WY Qunibi","year":"2002","unstructured":"Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl. 2002;82:S73-80. https:\/\/doi.org\/10.1046\/j.1523-1755.62.s82.15.x.","journal-title":"Kidney Int Suppl"},{"key":"2288_CR4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","volume":"67","author":"EW Young","year":"2005","unstructured":"Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int. 2005;67:1179\u201387. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00185.x.","journal-title":"Kidney Int"},{"key":"2288_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","volume":"52","author":"F Tentori","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52:519\u201330. https:\/\/doi.org\/10.1053\/j.ajkd.2008.03.020.","journal-title":"Am J Kidney Dis"},{"key":"2288_CR6","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","volume":"26","author":"J Floege","year":"2011","unstructured":"Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26:1948\u201355. https:\/\/doi.org\/10.1093\/ndt\/gfq219.","journal-title":"Nephrol Dial Transplant"},{"key":"2288_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/1744-9987.12030","volume":"17","author":"M Taniguchi","year":"2013","unstructured":"Taniguchi M, Fukagawa M, Fujii N, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17:221\u20138. https:\/\/doi.org\/10.1111\/1744-9987.12030.","journal-title":"Ther Apher Dial"},{"key":"2288_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney disease: improving global outcomes CKDMBD","year":"2017","unstructured":"Kidney disease: improving global outcomes CKDMBD. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD\u2013MBD). Kidney Int Suppl. 2017;7:1\u201359.","journal-title":"Kidney Int Suppl"},{"key":"2288_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1681\/ASN.2008060609","volume":"20","author":"T Isakova","year":"2009","unstructured":"Isakova T, Guti\u00e9rrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20:388\u201396. https:\/\/doi.org\/10.1681\/ASN.2008060609.","journal-title":"J Am Soc Nephrol"},{"key":"2288_CR10","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","volume":"30","author":"JL Fern\u00e1ndez-Mart\u00edn","year":"2015","unstructured":"Fern\u00e1ndez-Mart\u00edn JL, Mart\u00ednez-Camblor P, Dionisi MP, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30:1542\u201351. https:\/\/doi.org\/10.1093\/ndt\/gfv099.","journal-title":"Nephrol Dial Transplant"},{"key":"2288_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","volume":"42","author":"National Kidney Foundation","year":"2003","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-201.","journal-title":"Am J Kidney Dis"},{"key":"2288_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247\u201388. https:\/\/doi.org\/10.1111\/1744-9987.12058.","journal-title":"Ther Apher Dial"},{"key":"2288_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1681\/ASN.2020050598","volume":"32","author":"Y Isaka","year":"2021","unstructured":"Isaka Y, Hamano T, Fujii H, et al. Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol. 2021;32:723\u201335. https:\/\/doi.org\/10.1681\/ASN.2020050598.","journal-title":"J Am Soc Nephrol"},{"key":"2288_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jama.291.2.210","volume":"291","author":"P Greenland","year":"2004","unstructured":"Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210\u20135. https:\/\/doi.org\/10.1001\/jama.291.2.210.","journal-title":"JAMA"},{"key":"2288_CR15","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1001\/jama.2021.4807","volume":"325","author":"H Ogata","year":"2021","unstructured":"Ogata H, Fukagawa M, Hirakata H, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs. calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial. JAMA. 2021;325:1946\u201354. https:\/\/doi.org\/10.1001\/jama.2021.4807.","journal-title":"JAMA"},{"key":"2288_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","volume":"4","author":"RB Payne","year":"1973","unstructured":"Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4:643\u20136. https:\/\/doi.org\/10.1136\/bmj.4.5893.643.","journal-title":"Br Med J"},{"key":"2288_CR17","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1681\/ASN.V451205","volume":"4","author":"JT Daugirdas","year":"1993","unstructured":"Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt\/V: an analysis of error. J Am Soc Nephrol. 1993;4:1205\u201313. https:\/\/doi.org\/10.1681\/ASN.V451205.","journal-title":"J Am Soc Nephrol"},{"key":"2288_CR18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/s0272-6386(12)70364-5","volume":"15","author":"EG Lowrie","year":"1990","unstructured":"Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458\u201382. https:\/\/doi.org\/10.1016\/s0272-6386(12)70364-5.","journal-title":"Am J Kidney Dis"},{"key":"2288_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607\u201317. https:\/\/doi.org\/10.1053\/ajkd.1998.v31.pm9531176.","journal-title":"Am J Kidney Dis"},{"key":"2288_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1051-2276(98)90046-2","volume":"8","author":"SV Greene","year":"1998","unstructured":"Greene SV, Falciglia G, Rademacher R. Relationship between serum phosphorus levels and various outcome measures in adult hemodialysis patients. J Ren Nutr. 1998;8:77\u201382. https:\/\/doi.org\/10.1016\/s1051-2276(98)90046-2.","journal-title":"J Ren Nutr"},{"key":"2288_CR21","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/ndt\/14.9.2178","volume":"14","author":"SJ Marchais","year":"1999","unstructured":"Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant. 1999;14:2178\u201383. https:\/\/doi.org\/10.1093\/ndt\/14.9.2178.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2288_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12882-020-02088-x","volume":"21","author":"C Kato","year":"2020","unstructured":"Kato C, Fujii N, Miyakoshi C, Asada S, Onishi Y, Fukuma S, et al. Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2020;21(1):432. https:\/\/doi.org\/10.1186\/s12882-020-02088-x.","journal-title":"BMC Nephrol"},{"key":"2288_CR23","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/ndt\/gfr384","volume":"27","author":"M Koizumi","year":"2012","unstructured":"Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012;27:784\u201390. https:\/\/doi.org\/10.1093\/ndt\/gfr384.","journal-title":"Nephrol Dial Transplant"},{"key":"2288_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2022.2044472","volume":"21","author":"H Ogata","year":"2022","unstructured":"Ogata H, Takeshima A, Ito H. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles. Expert Opin Drug Saf. 2022;21:1\u20139. https:\/\/doi.org\/10.1080\/14740338.2022.2044472.","journal-title":"Expert Opin Drug Saf"},{"key":"2288_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2215\/CJN.00290109","volume":"4","author":"YW Chiu","year":"2009","unstructured":"Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4:1089\u201396. https:\/\/doi.org\/10.2215\/CJN.00290109.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2288_CR26","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/j.ekir.2021.06.030","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Sato Y, Ikejiri K, Kanda H, Fukagawa M. Effect of tenapanor on phosphate binder pill burden in hemodialysis patients. Kidney Int Rep. 2021;6:2371\u201380. https:\/\/doi.org\/10.1016\/j.ekir.2021.06.030.","journal-title":"Kidney Int Rep"},{"key":"2288_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10157-016-1310-8","volume":"21","author":"H Ogata","year":"2017","unstructured":"Ogata H, Fukagawa M, Hirakata H, et al. Design and baseline characteristics of the LANDMARK study. Clin Exp Nephrol. 2017;21:531\u20137. https:\/\/doi.org\/10.1007\/s10157-016-1310-8.","journal-title":"Clin Exp Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-022-02288-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-022-02288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T03:38:39Z","timestamp":1674272319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-022-02288-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2288"],"URL":"https:\/\/doi.org\/10.1007\/s10157-022-02288-9","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"1 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TM reported receiving consultancy fees from Zeon Medical Inc.; research grants from Boston Scientific; and speaker fees from Abbott Vascular, Cathworks, and Boston Scientific. MF reported receiving lecture fees from Bayer Yakuhin, Kyowa Kirin, Kissei, Ono Pharmaceutical and Sanwa Kagaku; and grants from Kyowa Kirin, Chugai, and Torii. TA reported receiving consulting and lecture fees from Bayer Yakuhin, Astellas, Kyowa Kirin, Kissei Pharmaceutical, Ono Pharmaceutical, Fuso Pharmaceutical Industry, and Torii Pharmaceutical; consulting fees from GlaxoSmithKline, JT Pharmaceutical, Nipro Corporation, Otsuka, and Sanwa Kagaku; and lecture fees from Chugai Pharmaceutical and Mitsubishi Tanabe Pharma. HO reported receiving lecture fees from Bayer Yakuhin, Kyowa Kirin, Torii Pharmaceutical, Otsuka, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma, Sumitomo Dainippon Pharm, Daiichi Sankyo, Kowa, and Ono Pharmaceutical; grants from Torii Pharmaceutical and Ono Pharmaceutical; and consulting fees from YL Biologics. NU reported receiving consultancy fees from TOA EIYO, Meiji Seika Pharma, AstraZeneca, Daiichi Sankyo Company Ltd, Eisai Co., Ltd, Sanwa Kagaku Kenkyusho Co., Ltd, Kyorin Pharmaceutical Co., Ltd., Sanofi K.K., NapaJen Pharma, GC Showayakuhin Corporation, Ito Life Science, Takata Pharmaceutical Co., Ltd., and SSP Co., Ltd.; and lecture fees from TOA EIYO, Meiji Seika Pharma, AstraZeneca, Daiichi Sankyo Company Ltd, and NapaJen Pharma. No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the LANDMARK study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This post-hoc analysis was approved by the ethics committee of Showa University (approval number 21-059-B).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the LANDMARK study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}